- Home
- Automated
- List of product information
- DECA-DURABOLIN INJECTION 25 MG/ML [SIN04300P]
DECA-DURABOLIN INJECTION 25 MG/ML [SIN04300P]
Active ingredients: DECA-DURABOLIN INJECTION 25 MG/ML
Last updated 26 October 2025
Product Info
DECA-DURABOLIN INJECTION 25 MG/ML
[SIN04300P]
Product information
Active Ingredient and Strength | NANDROLONE DECANOATE - 25 MG/ML |
Dosage Form | INJECTION |
Manufacturer and Country | EVER PHARMA JENA GMBH - GERMANY |
Registration Number | SIN04300P |
Licence Holder | DCH AURIGA SINGAPORE |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | A14AB01 |
4.1 Therapeutic indications
Treatment of osteoporosis
For the palliative treatment of selected cases of disseminated mammary carcinoma in women.
As an adjunct to specific therapies and dietary measures in pathologic conditions characterized by a negative nitrogen balance
4.2 Posology and method of administration
Deca-Durabolin should be administered by deep intramuscular injection.
For treatment of osteoporosis: 50 mg once every 3 weeks
For the palliative treatment of selected cases of disseminated mammary carcinoma in women: 50mg every 2 – 3 weeks
As an adjunct to specific therapies and dietary measures in pathologic conditions characterized by a negative nitrogen balance: 25–50 mg every 3 weeks.
N.B. For an optimal therapeutic effect it is necessary to administer adequate amounts of vitamins, minerals and protein in a calorie-rich diet.
Safety and efficacy have not been adequately determined in children and adolescents (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
4.3 Contraindications
Pregnancy (see Section 4.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)
Known or suspected carcinoma of the prostate or breast in the male (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)
Hypersensitivity to the active substance or to any of the excipients, including arachis oil. Deca-Durabolin is therefore contraindicated in patients allergic to peanuts or soya (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)